Chemical Management
Arcadium Lithium | January 08, 2024
Arcadium Lithium plc announced the completion of the all-stock merger of equals between Allkem and Livent. The new, combined company is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people's lives and accelerate the transition to a clean energy future. With roughly U.S. $1.9 billion of combined total revenue in 2022 and a global team of more than 2,600 employees, Arcadium Lithium is one of the largest integrated producers of lithium chemicals in the world.
Paul Graves, Chief Executive Officer of Arcadium Lithium, said: "As one of the leading global producers of lithium chemicals, Arcadium Lithium has the resources, scale and expertise to meet the growing needs of our rapidly changing industry. We are a leader in every major lithium extraction process – from hard rock mining to conventional pond and DLE-based brine processing – and vertically integrated, from resource to chemical manufacturing, in strategic locations around the world. This will open doors to new opportunities and strengthen our ability to deliver value to our customers, investors, employees and communities."
Mr. Graves continued: "It is a privilege for me to lead this great company forward with such an incredible team. This transformational merger would not have been possible without the hard work and commitment of our integration planning teams over the past months. I want to thank them and all of our employees around the world for getting us to this position. Together, we are launching an exciting new company that combines the strengths and storied legacies of two incredible organizations, both with an wavering commitment to safe, responsible and sustainable operations. We look forward to building on this strong foundation and leading our industry forward."
Arcadium Lithium ordinary shares will begin trading today on the NYSE under the ticker "ALTM." Arcadium Lithium also maintains a foreign exempt listing on the ASX (via the issue of CHESS Depositary Instruments (CDIs) to Allkem shareholders) and will commence trading on a normal settlement basis on the ASX under the ticker "LTM" at 10:00am (AEDT) on January 5, 2024. Allkem shareholders received either: (a) one Arcadium Lithium ASX listed CDI; or (b) one Arcadium Lithium NYSE listed share depending where they resided and what election (if any) they had made for each Allkem ordinary share held, except for shareholders in certain ineligible jurisdictions, who will receive cash proceeds from the sale of the Arcadium Lithium CDIs in lieu of such CDIs after closing. Livent shareholders received 2.406 Arcadium Lithium NYSE listed ordinary shares for each Livent share held.
Read More
Market Outlook
Lummus Technology | January 10, 2024
Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced a major investment in Resynergi, a pioneering leader in plastic recycling technology, to scale production of Resynergi's modular Continuous Microwave Assisted Pyrolysis (CMAP) technology. CMAP converts plastic waste into reusable materials at a rate 20 times faster than traditional pyrolysis methods. Lummus' President and Chief Executive Officer, Leon de Bruyn, will also join Resynergi's board of directors.
"Lummus' is not only investing in Resynergi, we are partnering with true innovators to develop and scale sustainable solutions that advance the circular economy," said Leon de Bruyn, President and Chief Executive Officer of Lummus Technology. "Combining our global licensing expertise with Resynergi's proven CMAP technology will help us accelerate the conversion of plastic waste into high-quality, reusable material. I also look forward to collaborating with Resynergi's team and the board of directors to help reduce the carbon footprint of conventional plastics production and meet the growing demand for recycled plastics."
"The investment from Lummus, along with their global licensing expertise, will allow us to scale our innovative recycling technology and collectively reduce our dependence on fossil fuels by addressing plastic waste and accelerate plastic circularity," said Resynergi Chief Executive Officer Brian Bauer.
With an estimated 70% growth in plastic waste by 2050, Resynergi's modular CMAP technology is positioned to scale waste conversion creating positive social and environmental impact.
Key Resynergi CMAP Technology Highlights
Modular Design – allows for rapid deployment and scalability, making advanced recycling more affordable and versatile.
Compact Footprint – 10X smaller reactor footprint and system-on-a-skid design eliminates local waste management and municipality's typical square footage requirements for a "recycling plant."
Rapid Time to Value – Modules scale horizontally, allowing deployment and start up in weeks, rather than years.
Faster Conversion – Harnessing microwave energy, plastic molecules are broken down 100X faster than traditional pyrolysis reactors.
High Quality Output – Oil products that meet standards set by refinery partners for chemical recycling.
Clean Energy Efficiency and Environmentally Friendly Process – CMAP generates clean products with up to 68% CO2e reduction.
About Lummus Technology
Lummus Technology is the global leader in developing technology solutions that make modern life possible and focus on a more sustainable, low carbon future. We license process technologies in clean fuels, renewables, petrochemicals, polymers, gas processing and supply lifecycle services, catalysts, proprietary equipment and digitalization to customers worldwide.
About Resynergi
Resynergi, headquartered in Rohnert Park, CA, is an advanced recycling technology company accelerating plastic circularity to protect human health and the environment. Its innovative, scalable and environmentally efficient Continuous Microwave Assisted Pyrolysis (CMAP) technology reduces fossil-based resource dependency by converting plastic into its molecular building blocks to be used to create new materials. Resynergi works with recycling organizations to secure used and hard-to-recycle plastics, effectively diverting millions of pounds of plastic from landfills and oceans. Its proprietary process creates clean, liquid hydrocarbons serving as feedstock for the synthesis of new plastics.
Read More
Chemical Management
Charter Next Generation | January 30, 2024
Charter Next Generation (CNG), a leading provider of sustainable films, announced that it has expanded its GreenArrow portfolio with a new line of cavitated polyethylene (PE) films. Developed in collaboration with VOID Technologies (VOID), the new recycle-ready films meet the rapidly growing demand for flow wrap and confectionery applications. Using VOID's patented VO+™ PE Voiding Agent Masterbatch and Machine Direction Orientation (MDO) film processing, CNG has successfully developed high-performing PE film structures that are opaque yet compatible with existing PE recycling streams making more packaging suitable for recycling.
Adoption of MDO PE film is a rapidly growing industry trend as it enables recyclable, high-performing flexible packaging. By using VO+ Masterbatch, CNG can now produce thin gauge voided MDO PE films that offer a combination of low density and high opacity not achievable with mineral additives such as TiO2 pigments or CaCO3 cavitation agents. This innovation creates a unique PE-based recycle-ready alternative to conventional PP-based substrates that often require biaxial orientation.
"CNG continues to raise the bar and re-invent packaging with a sustainability-first mindset. Using VOID's patented VO+ technology enables us to achieve the high opacity, ease of processing, and recycle-ready performance we are targeting for these films. This in turn allows our customers to reduce their use of virgin materials and process their packaging in existing polyethylene film recycling streams," said Brent Greiner, Vice-President of Technology at Charter Next Generation.
The VO+ PE Masterbatch is added to PE resin to create nano and micro-scale voids, reducing density and creating high levels of opacity via light scattering through the voided structure. VOID's latest VO+ PE Masterbatch product is compliant with direct food contact standards in North America and Europe and has passed key recycling standards.
James Gibson, CEO of VOID Technologies, commented, "CNG is a highly innovative and forward-thinking company. We are delighted with this collaboration and to be part of launching this new generation of recycle-ready voided PE films. As we look to the future, we are excited to be working with CNG across a range of projects that directly address sustainability and recycling targets."
About Charter Next Generation
Charter Next Generation (CNG) is North America's leading producer of highly engineered solutions used in the food, consumer, healthcare, and industrial markets. Committed to a sustainability-first approach, CNG leverages material science to engineer materials that help companies meet and exceed their sustainability goals. Known for world-class manufacturing capabilities and an innovation-driven approach, CNG operates fifteen facilities and employs over 2,200 employees and is a proud partner of Ownership Works®—a nonprofit partnering with companies to enable shared ownership, granting employees a stake in the value they create.
About VOID Technologies
VOID is a materials science company accelerating the transition to more sustainable plastics and packaging. The company combines its VO+ cavitation technology and R&D labs to help plastic and packaging companies rapidly develop new innovative products with a reduced environmental footprint. VOID's extensively patented VO+ technology was first conceived as part of a research initiative at Kimberly-Clark. Soon after, in 2015, VOID was launched as an independent company. Today, VOID has R&D labs and a compound manufacturing facility based in Neenah, Wisconsin (USA) and has commercial teams in Canada, France, and the UK.
Read More
Chemical Technology
Chemify | January 23, 2024
Chemify and Prepaire™ Labs announced to expand their partnership with an additional program to tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids as pain modulators, as well as drugs tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire’s integrated novel open collaboration drug discovery platform. The project, named Toxifree, comes in response to the FDA’s Center for Drug Evaluation and Research (CDER) requesting drugmakers and researchers to develop treatments for stimulant use disorder, hoping to address a major gap in the addiction crisis response.
After a successful initial partnership, Chemify and Prepaire are now aiming to leverage Chemify's Chemputation technology which enables the automated and integrated design, discovery, and synthesis of complex molecules on demand using a chemical programming language and Prepaire's advanced open-architecture drug development platform.
Under the terms of this partnership, Chemify will design and discover novel compounds to identify Opioid-derived hits and develop them further into candidates. Chemify will receive at least USD $30 million in payments and pre-negotiated, success-driven clinical and regulatory milestones for each developed molecule, as well as single digit royalties on any resulting products.
Lee Cronin, Chemify's Founder and CEO and Regius Professor of Chemistry at the University of Glasgow has extensive experience leading research efforts to develop solutions for the opioid crisis. Cronin lead a team that won several NIH-prize challenges including winning the grand runner up prize for the design, discovery and automated synthesis of next generation, safer and non-addictive drug-candidates to help address the opioid crisis.
"We are extremely excited to combine Chemify's technology for molecular design, discovery and synthesis with the integrated Prepaire platform to expand our collaboration and create a fully integrated, digitally driven drug discovery approach. With this partnership we are breaking ground on a new pain modulation discovery program that aims to tackle the global need for better and non-addictive pain medication. With our unique design approach guided by Chemputation, we are utilizing an evolutionary approach to discovering novel compounds to solve this devastating and critical healthcare need," said Professor Lee Cronin, Chemify's Founder and CEO.
"Our partnership with Chemify allows our discovery platform to integrate directly with Chemify's chemical space exploration approach, enabling us to access novel chemical matter that would have otherwise been inaccessible. As we progress our collaboration, we are aiming to build an integrated approach that can be used for many more indications beyond novel pain modulators. There aren't any approved treatments to help address addiction to opioids, whose use has surged in recent years. The purpose of this FDA guidance is to assist in the clinical trial designs for the development of novel drugs to support indications for treatment of moderate to severe cocaine use disorder, treatment of moderate to severe methamphetamine use disorder, or treatment of moderate to severe prescription stimulant use disorder," said Dr Vicent Ribas, Prepaire’s Co-Founder.
About Chemputation
Digital chemistry applies principles of computation to chemistry for programable chemistry and Chemify has developed the underpinning infrastructure to make this possible for chemical discovery and synthesis. Like a computer program, digital chemistry programs can automatically run chemical experiments, make new molecules, and ensure that complex chemical recipes are always accessible and perfectly reproducible. Chemical programs are precise pieces of code that allow fully transparent and reliable operation allowing the implementation of AI and other techniques with full audit and safety.
About Chemify
Based in Glasgow, Chemify is a pioneering company digitizing chemistry to provide world-leading pharmaceutical, biotechnology, and industrial partners access to an exponentially growing space of novel molecules and materials. By leveraging decades of chemistry experience, hardware robotics, and artificial intelligence, Chemify's Chemputation technology enables companies to access an end-to-end workflow for drug discovery, molecule synthesis, and materials discovery. Chemify was founded by CEO Lee Cronin based on conceptual advancements from Cronin's Digital Chemistry Laboratory at the University of Glasgow in Scotland. By building the infrastructure to digitize chemistry, Chemify is reimagining chemical research, discovery and manufacturing to benefit all of humanity by accelerating advances across chemistry with a focus on medicine and functional materials.
About Prepaire Labs
Prepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases. Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models that optimize genetics, cell-type, environment, and multidimensional data collection for increased predictability of human clinical outcomes. A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE.
Read More